Compare Baxter International Inc (BAX) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs BridgeBio Pharma Inc — how do they compare? Baxter International Inc trades at $27.61 (market cap $14.27B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B). The key difference: Baxter International Inc and BridgeBio Pharma Inc are close in size by market cap, and Baxter International Inc pays a 0.14% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BAX | BBIO | |
|---|---|---|
Market Cap | $14.27B | $16.36B |
Sector | Health | Health |
52-Week High | $28.35 | $90.17 |
52-Week Low | $15.80 | $47.29 |
Enterprise Value | $21.79B | $18.14B |
Dividend Yield | 0.14% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
